Drug development advances in human genetics‐based targets
MedComm · 2024-02 · 5 (2)
DOI: 10.1002/mco2.481 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 09.02.2024. Verfasst von Xiaoxia Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 314 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Drug development is a long and costly process, with a high degree of uncertainty from the identification of a drug target to its market launch. Targeted drugs supported by human genetic evidence are expected to enter phase II/III clinical trials or be approved for marketing more quickly, speeding up the drug development process. Currently, genetic data and technologies such as genome‐wide association studies (GWAS), whole‐exome sequencing (WES), and whole‐genome sequencing (WGS) have identified and validated many potential molecular targets associated with diseases. This review describes the structure, molecular biology, and drug development of human genetics‐based validated beneficial loss‐of‐function (LOF) mutation targets (target mutations that reduce disease incidence) over the past decade. The feasibility of eight beneficial LOF mutation targets (PCSK9, ANGPTL3, ASGR1, HSD17B13, KHK, CIDEB, GPR75, and INHBE) as targets for drug discovery is mainly emphasized, and their research prospects and challenges are discussed. In conclusion, we expect that this review will inspire more researchers to use human genetics and genomics to support the discovery of novel therapeutic drugs and the direction of clinical development, which will contribute to the development of new drug discovery and drug repurposing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universi…
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica Yantai Shandong China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery Yantai Shandong China.
- State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai China.
ORCID-Profile: Xiaoxia Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Zhang, X., Yu, W., Li, Y., Wang, A., Cao, H., & Fu, Y. (2024). Drug development advances in human genetics‐based targets. MedComm, 5(2). https://doi.org/10.1002/mco2.481
Vancouver
Zhang X, Yu W, Li Y, Wang A, Cao H, Fu Y. Drug development advances in human genetics‐based targets. MedComm. 2024;5(2). doi:10.1002/mco2.481
BibTeX
@article{Zhang2024,
author = {Zhang, Xiaoxia and Yu, Wenjun and Li, Yan and Wang, Aiping and Cao, Haiqiang and Fu, Yuanlei},
title = {Drug development advances in human genetics‐based targets},
journal = {MedComm},
year = {2024},
volume = {5},
number = {2},
doi = {10.1002/mco2.481}
}
EUVIMED